Pharmaceutical initiatives to combat atherosclerosis--what to do with the good, the bad, and the ugly lipoproteins.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Seminars in Vascular Surgery

• Publication date

  2002-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0895-7967(02)70020-3PMID 12478495
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Primary prevention of coronary heart disease

  2008cited by this paper
• Lipoprotein (a) level and mortality in patients with critical lower limb ischaemia.

  2001cited by this paper
• High-density lipoprotein cholesterol and ischemic stroke in the elderly: the Northern Manhattan Stroke Study.

  2001cited by this paper
• Statins and Bone: Myth or Reality?

  2001cited by this paper
• Clinical inquiries. What laboratory monitoring is appropriate to detect adverse drug reactions in patients on cholesterol-lowering agents?

  2001cited by this paper
• Reduction of Stroke Events With Pravastatin: The Prospective Pravastatin Pooling (PPP) Project

  2001cited by this paper
• Structural Mechanism for Statin Inhibition of HMG-CoA Reductase

  2001cited by this paper
• Fluvastatin Lowers Atherogenic Dense Low-Density Lipoproteins in Postmenopausal Women With the Atherogenic Lipoprotein Phenotype

  2001cited by this paper
• Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial.

  2001cited by this paper
• Pravastatin and the Development of Diabetes Mellitus: Evidence for a Protective Treatment Effect in the West of Scotland Coronary Prevention Study

  2001cited by this paper
• Do statins cause cancer? A meta-analysis of large randomized clinical trials.

  2001cited by this paper
• Effects of fenofibrate and gemfibrozil on plasma homocysteine.

  2001cited by this paper
• Statins for the prevention of Alzheimer's disease.

  2001cited by this paper
• Cholesterol reduction and non-illness mortality: meta-analysis of randomised clinical trials

  2001cited by this paper
• Novel clinical markers of vascular wall inflammation.

  2001cited by this paper
• Are statins anti-inflammatory?

  2000cited by this paper
• Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels.

  2000cited by this paper
• Do triglycerides provide meaningful information about heart disease risk?

  2000cited by this paper
• Hyperfibrinogenemia is associated with specific histocytological composition and complications of atherosclerotic carotid plaques in patients affected by transient ischemic attacks.

  2000cited by this paper
• Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects.

  1999cited by this paper
• Serum homocysteine increases after therapy with fenofibrate or bezafibrate.

  1999cited by this paper
• Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril).

  1999cited by this paper
• Niacin treatment increases plasma homocyst(e)ine levels.

  1999cited by this paper
• New perspectives on the management of low levels of high-density lipoprotein cholesterol.

  1999cited by this paper
• Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials.

  1999cited by this paper
• Blood pressure, cholesterol, and stroke in eastern Asia

  1998cited by this paper
• Antiatherothrombotic properties of statins: implications for cardiovascular event reduction.

  1998cited by this paper
• Mechanism of action of fibrates on lipid and lipoprotein metabolism.

  1998cited by this paper
• Usual care dietary practice, achievement and implications for medication in the management of hypercholesterolaemia. Data from the U.K. Lipid Clinics Programme.

  1998cited by this paper
• Effect of HMGcoA Reductase Inhibitors on Stroke

  1998cited by this paper
• Atorvastatin action involves diminished recovery of hepatic HMG-CoA reductase activity.

  1998cited by this paper
• Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study.

  1998cited by this paper
• Efficacy and muscle safety of fluvastatin in cyclosporine-treated cardiac and renal transplant recipients: an exercise provocation test.

  1998cited by this paper
• Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

  1998cited by this paper
• Effect of niacin supplementation on fibrinogen levels in patients with peripheral vascular disease.

  1998cited by this paper
• Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia.

  1998cited by this paper
• Clinical Pharmacokinetics of Fibric Acid Derivatives (Fibrates)

  1998cited by this paper
• Blood pressure, cholesterol, and stroke in eastern Asia. Eastern Stroke and Coronary Heart Disease Collaborative Research Group.

  1998cited by this paper
• Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

  1998cited by this paper
• Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin.

  1998cited by this paper
• Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS).

  1998cited by this paper
• Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials.

  1997cited by this paper
• Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S)

  1997cited by this paper
• A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients witb hypercholesterolemia

  1997cited by this paper
• Modulation of lipoprotein(a) atherogenicity by high density lipoprotein cholesterol levels in middle-aged men with symptomatic coronary artery disease and normal to moderately elevated serum cholesterol. Regression Growth Evaluation Statin Study (REGRESS) Study Group.

  1997cited by this paper
• Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia.

  1997cited by this paper
• Attenuation by gemfibrozil of expression of plasminogen activator inhibitor type 1 induced by insulin and its precursors.

  1997cited by this paper
• A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia.

  1997cited by this paper
• Cumulative effects of high cholesterol levels, high blood pressure, and cigarette smoking on carotid stenosis.

  1997cited by this paper
• Reductase inhibitor monotherapy and stroke prevention.

  1997cited by this paper
• Beyond low-density lipoprotein cholesterol. A perspective on low high-density lipoprotein disorders and Lp(a) lipoprotein excess.

  1996cited by this paper
• Meta-analysis, clinical trials, and transferability of research results into practice. The case of cholesterol-lowering interventions in the secondary prevention of coronary heart disease.

  1996cited by this paper
• Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project.

  1996cited by this paper
• Hypocholesterolemic actions of atorvastatin are associated with alterations on hepatic cholesterol metabolism and lipoprotein composition in the guinea pig.

  1996cited by this paper
• The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

  1996cited by this paper
• Carcinogenicity of lipid-lowering drugs.

  1996cited by this paper
• Effect of gemfibrozil on levels of lipoprotein[a] in type II hyperlipoproteinemic subjects.

  1996cited by this paper
• Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice.

  1996cited by this paper
• Inhibitors of cholesterol biosynthesis increase hepatic low-density lipoprotein receptor protein degradation.

  1996cited by this paper
• A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction.

  1996cited by this paper
• Gemfibrozil stimulates apolipoprotein A-I synthesis and secretion by stabilization of mRNA transcripts in human hepatoblastoma cell line (Hep G2).

  1996cited by this paper
• Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.

  1996cited by this paper
• Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study.

  1996cited by this paper
• Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor.

  1995cited by this paper
• Combination Therapy with Colestipol and Psyllium Mucilloid in Patients with Hyperlipidemia

  1995cited by this paper
• Discontinuation of antihyperlipidemic drugs--do rates reported in clinical trials reflect rates in primary care settings?

  1995cited by this paper
• Percentage change rather than plasma level of LDL-cholesterol determines therapeutic response in coronary heart disease.

  1995cited by this paper
• Effect of pravastatin on outcomes after cardiac transplantation.

  1995cited by this paper
• Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S)

  1995cited by this paper
• Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study.

  1995cited by this paper
• Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS).

  1995cited by this paper
• Alcohol consumption and mortality among women.

  1995cited by this paper
• Nicotinic acid as a lipoprotein-altering agent. Therapy directed by the primary physician.

  1994cited by this paper
• Pravastatin, lipids, and major coronary events.

  1994cited by this paper
• Drug treatment of dyslipoproteinemia.

  1994cited by this paper
• Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial.

  1994cited by this paper
• Comparative effects of lovastatin and niacin in primary hypercholesterolemia

  1994cited by this paper
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

  1994cited by this paper
• Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia.

  1994cited by this paper
• Low-Dose Combined Therapy with Fluvastatin and Cholestyramine in Hyperlipidemic Patients

  1994cited by this paper
• Safety of combined pravastatin-gemfibrozil therapy.

  1994cited by this paper
• A Quarter Century of Drug Treatment of Dyslipoproteinemia, With a Focus on the New HMG‐CoA Reductase Inhibitor Fluvastatin

  1993cited by this paper
• Myocardial injury: the acute phase response and lipoprotein metabolism.

  1993cited by this paper
• Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia.

  1993cited by this paper
• Gemfibrozil-lovastatin-associated myalgia.

  1993cited by this paper
• Single‐Dose Pharmacokinetics of Pravastatin and Metabolites in Patients with Renal Impairment

  1992cited by this paper
• Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias.

  1992cited by this paper
• Joint Effects of Serum Triglyceride and LDL Cholesterol and HDL Cholesterol Concentrations on Coronary Heart Disease Risk in the Helsinki Heart Study: Implications for Treatment

  1992cited by this paper
• THE EFFECTS OF PRAVASTATIN ON HYPERLIPIDEMIA IN RENAL TRANSPLANT RECIPIENTS1

  1992cited by this paper
• Unstable myocardial ischemia after the initiation of niacin therapy.

  1991cited by this paper
• Niacin-induced hepatitis: a potential side effect with low-dose time-release niacin.

  1991cited by this paper
• Gemfibrozil-induced myopathy.

  1991cited by this paper
• Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy.

  1990cited by this paper
• Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus.

  1990cited by this paper
• Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia

  1990cited by this paper
• HMG-CoA reductase inhibitors for treatment of hypercholesterolemia.

  1988cited by this paper
• Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.

  1987cited by this paper
• The role of plasma lipids in carotid bifurcation atherosclerosis

  1985cited by this paper
• Serum HDL/total cholesterol ratio and blood pressure in asymptomatic atherosclerotic lesions of the cervical carotid arteries in men.

  1985cited by this paper
• Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man.

  1981cited by this paper

• Synthesis, characterization and in vitro hydrolysis of a gemfibrozil-nicotinic acid codrug for improvement of lipid profile.

  2011cites this paper